ACCELERATING DISCOVERIES WITH CRISPR SCREENING

A good screen starts with a good library. Our proprietary PRCISRTM technology delivers CRISPR libraries with unmatched uniformity, thereby increasing resolution and allowing the expansion of the search space with less cell material. PRCISRTM combinatorial libraries enable the unbiased screening for genetic interactions.

We provide the following CRISPR services: libraries, screening, and computational analyses.

PRCISR™ CRISPR

Vivlion’s CRISPR-enabled Discovery Platform

PRCISRTM CRISPR key features

Vivlion's PRCISR CRISPR key features

 Uniformity matters!

Explore the benefits of working with Vivlion® 

Vivlion - library Optimal strategy implementation: Our dedicated team provides comprehensive support in planning your CRISPR experiments.
Uniformity and completeness: Our uniformly distributed PRCISRTM  CRISPR libraries ensure that all your target genes are properly represented.
Vivlion - library Dual-targeting enhances performance: PRCISRTM CRISPR libraries achieve > 90% gene editing efficiency.
Vivlion - library Downscale your experiment: PRCISRTM CRISPR libraries allow working with limited cell material (e.g. iPS cells, primary) and deliver reliable results at low coverage.
Vivlion - library Multigenic exploration: Combinatorial PRCISRTM solutions enable genetic interaction mapping and expand the search space for target discovery.
Vivlion - library Tailored services: We deliver tailored screening and bioinformatic services, from experimental planning to sophisticated tools for data analysis and integration.

Link to our proprietary PRCISRTM technology

“We are thrilled to work with Vivlion for their high-quality CRISPR libraries that have excellent guide representation. The superb quality of their products and technical support has made them a highly valued contributor. Vivlion’s genome-wide CRISPR libraries will enable us to continue discovering synthetic lethal drug targets with lower false negative rates, which will ultimately benefit cancer patients in need of new therapeutic options.”

Jordan Young, PhD

Director of SNIPRx® platform, Repare Therapeutics

Contact us

We would like to hear more about your CRISPR questions and applications – please reach out to us by completing the following form:

     

    Vivlion - Contact
    Cookie Consent Banner by Real Cookie Banner